CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 113 enrolled
Drug / intervention
Ropivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03077919
NCT03077919N/ACompleted
CompareCT.gov

A Randomized, Sham-procedure-controlled, Blinded Study to Evaluate the Effectiveness and Acceptability of Right-sided Stellate Ganglion Block for Treatment of Posttraumatic Stress Disorder Symptoms

RTI International·interventional·Posted Mar 13, 2017·Updated May 13, 2020

In Brief

A clinical study evaluating Ropivacaine and Sham treatment for PostTraumatic Stress Disorder. Completed, enrolled 113 participants across 3 sites in 2 countries.

Detailed Summary

This is a multisite, randomized, blinded, sham-procedure-controlled study to evaluate the efficacy of right-sided stellate ganglion block (SGB) on the acute symptomatology of Post traumatic Stress Disorder (PTSD), evaluated by the Clinician-Administered PTSD Scale (CAPS-5) clinical interview at pre-treatment and at 8 weeks. This entry describes the effectiveness study.The acceptability study is described in a separate entry.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostTraumatic Stress Disorder
CountriesGermany, United States
CollaboratorsWomack Army Medical Center, Tripler Army Medical Center, Landstuhl Regional Medical Center

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 13, 2017
Enrollment StartMay 25, 2016
Primary CompletionJun 9, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.3 years ago

Interventions

Ropivacainedrug

0.5% ropivacaine

Sham treatmentdrug

preservative-free normal saline